Browsing Category
Pharma Industry News
4730 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Is dose escalation the new edge in the obesity drug war? Why GLP-1 rivals are raising the ceiling on efficacy
High-dose GLP-1 drugs like 7.2 mg Wegovy are redefining obesity treatment in 2025. Find out how dose escalation is shifting efficacy expectations.
Novo Nordisk’s amycretin delivers 14.5% weight loss in type 2 diabetes trial: A dual-agonist breakthrough?
Novo Nordisk’s amycretin delivers up to 14.5% weight loss in type 2 diabetes trial. Explore the trial data and what’s next in the GLP‑1 drug race.
Can 7.2 mg Wegovy redefine the weight loss standard in obesity treatment?
Novo Nordisk files for FDA approval of 7.2 mg Wegovy with fast-track priority review. See what this higher dose means for the future of obesity treatment.
What Vanda’s December FDA deadlines could mean for motion sickness drug market leadership
Vanda Pharmaceuticals confirms FDA extension of tradipitant clinical hold review to December 5, while motion sickness NDA remains on track for December 30 decision.
Can Ascletis’ obesity pipeline redefine oral and monthly peptide therapy in 2026?
Find out how Ascletis’ oral and monthly obesity therapies are challenging industry norms with next-gen peptide technology.
Pasithea Therapeutics raises $60m in discounted public offering as biotech funding momentum returns
Find out how Pasithea Therapeutics’ $60 million stock offering reshapes its clinical runway, dilution outlook, and investor sentiment.
Can Ascendis Pharma’s TransCon CNP still win FDA approval after the review extension?
FDA delays decision on Ascendis Pharma’s dwarfism drug TransCon CNP to February 2026 due to protocol revisions. See how this affects approval odds and launch.
Why Imugene is using a virus to “mark” tumors for CAR-T attack—and what JW Therapeutics brings to the table
Find out how Imugene and JW Therapeutics plan to make solid tumors respond to CD19 CAR-T therapy using an oncolytic virus strategy.
Can Innovent’s PECONDLE rewrite China’s psoriasis treatment playbook with its IL-23p19 antibody?
Innovent Biologics wins NMPA nod for PECONDLE, China’s first IL-23p19 psoriasis biologic. Learn how this reshapes autoimmune therapy options for millions.
Vanda Pharmaceuticals (NASDAQ: VNDA) gains after FDA sets new December 5 date for tradipitant re-review
Vanda Pharmaceuticals moves closer to FDA approval for tradipitant in motion sickness while targeting the GLP-1 side effect market. Find out what’s next.